Re: Zenith-Oncology Pipeline
in response to
by
posted on
Mar 19, 2021 11:19AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
I'm one of the people who has been looking for a NASDAQ IPO, much as narmac stated, to reach a broad investment market with deep pockets for biotech from a less risk averse market than Canada. I believe that Zenith and RVX have very interesting and compelling stories to tell. They just need a competent story teller and there would be lots of interest from US investors.
Perhaps the science is not at a stage that would support much value. I don't know, but Repare did their NASDAQ with no drugs in clinical trials and it went out at $20USD and sold out. Of course they had a huge contract with a drug company (GSK???) in place.
What I am wondering in my simple little mind is that zen3694 is an epigenetic compound that may impact many cancers and enhance many SOC existing compounds made by many different BPs. Therefore would not the most lucrative path be to partner with a manufacturer and distributor and set up a company to sell to as many BPs as are interested in buying the drug? Thus Zenith would become a pharma selling to other pharmas. This would provide ongoing cash flow and not restrict the drug to 1 cancer or BP. Of course this would require a new management with the appropriate skill sets.
At the end of the day I'm guessing that Don is going to end up being a hero just by sitting back and milking the system and letting the science prove itself no matter how long it takes. I would call Dr Wong and his science team the real heros but Don will be perceived as the guy that made it happen and good for him.
Just a thought. And, I have never seen evidence that Don has a strategy.
GLTA
Toinv